Key inclusion/exclusion criteria are noted here; the lists are not exhaustive.
 

• Secondary endpoint: change in Hb level from baseline* to Week 24 (ITT analysis).¹ In the secondary analyses the type I error rate was not protected^† and therefore the significance (p-value) is not robust
• Improvements in Hb level with Oxbryta® 1,500 mg/day were observed from as early as 2 weeks^1,3

• Secondary endpoint: change in Hb level from baseline to Week 24¹
• Shown here are individual patient-level changes in Hb from baseline to Week 24 among patients who completed 24 weeks of treatment (per protocol analysis)³

• Secondary endpoint: change from baseline to Week 24 in laboratory markers associated with haemolysis¹
• Pre-specified exploratory endpoint: change from baseline to Week 72 in laboratory markers associated with haemolysis⁷

• Shown here are differences in the percentages of patients treated with Oxbryta® 1,500 mg once daily or placebo who had an Hb response (defined as an Hb increase of >1.0 g/dL [0.62 mmol/L] from baseline at Week 24) across subgroups⁴

• The increase in Hb levels from baseline with Oxbryta® 1,500 mg/day was maintained through Week 72 in the HOPE trial^3,7
• Pre-specified exploratory endpoint: change in Hb levels from baseline to Week 72⁷

• The median duration of follow-up was 72.1 weeks (IQR 42.3–73.0) in the Oxbryta® group and 72.1 weeks (IQR 61.2–72.9) in the placebo group⁷
• The most frequently reported adverse events unrelated to sickle cell disease with an incidence of ≥20% in the Oxbryta® group were headache, diarrhoea and arthralgia⁷
• Serious adverse events unrelated to sickle cell disease were generally balanced across the treatment groups (25/88 [28%] patients in the Oxbryta® group and 23/91 [25%] patients in the placebo group)⁷